Key Highlights
-
LBT delivers positive operating cash flow for the Quarter of $0.4 million
-
Two APAS® Independence sales completed during the Quarter. Sales revenue of $0.5 million
-
Updated Product Pipeline Strategy announced, expanding application of APAS® technology
- $1.5 million funding for benchtop APAS® instrument through MTPConnect’s CTCM program
- Successful APAS® Pharma proof-of-concept completed with multinational pharmaceutical company
-
LBT launches Entitlement Offer seeking to raise $3.5 million to support sales growth
-
30 September 2022 cash balance of $2.8 million plus $1.9 million in near term receivables
For more information, download the attached PDF.
Download this document
